Guide:With a series of promote policies for the development of stem cell industry in China, relevant departments and units have responded positively to the call,and followed the development tendency to accelerate the development of stem cell research and transformation projects.
According to statistical data, from the launch of the first batch of national key R&D plan pilot projects in 2015, the key projects has been supported by the Central Finance for four consecutive years: 25 projects with 480 billion yuan support in 2016;43 projects with 940 billion yuan in 2017; 30 projects with 580 billion yuan in 2018,and the Central Finance grant 400 billion yuan to support 12 stem cell research directions in 2019, for totally 2.5 billion yuan, which fully reflects that China pays high attention to stem cell and regenerative medicine in the national top plan of science and technology innovation system.
The number of stem cell clinical projects on record has been constantly increased since 2019. Up to now, the National Health and Fitness Commission has published 62 recorded clinical projects for stem cells.The diseases that stem cell clinical therapies researched involve many diseases in all major systems of human body.
Under the guidance of global technology and application, and the promotion of a series of policies in our country, stem cells and regenerated medical have been listed as one of the important directions of Healthy China in 2030. With the policies’ leading, relevant personnel and research institutes constantly input financial resources,material resources and personnel resources to promote the development of stem cell treatment technology in China.
It Quiet Various in Different Fields in China and Global Stem Cell Industry
The diseases that umbilical cord blood stem cells in China treat are mainly blood system diseases, among which 23% are Aplastic Anemia, 19% are β-Thalassemia and Acute Myelogenous Leukemia.Compared with umbilical cord blood stem cells, the scope of diseases that umbilical mesenchymal stem cells treat are wider, which involve disease applications in every key system of human body.Started from 2015, the policies related to stem cells became relaxed, which provide advantages for the development of downstream industry of stem cells. Under the double stimulus of policies and fund, stem cells producers may take it as the long distance target that bringing out mature stem cell drugs and technology,and at the same time break through hospitals to conduct stem cell therapy and achieve the connection between midstream and downstream.
As stem cells with the ability to self-replicate and provide self-renewal and repair through cell division,it has great development potential and clinical application value in disease treatment, tissue repair, anti-aging beauty and other fields. In recent years, it has become one of the important directions in the field of life science and has been widely concerned in the world.
On the basis of the national policies to promote the development and clinical application of stem cells, representative hospitals in China have made remarkable achievements in the clinical application and rehabilitation treatment of stem cells.
China Strongly Supports the Application of Stem Cell Drugs
In 2008, the official website of the National Health Commission published the Reply to Proposal No. 4443 of the First Session of the 13th National Committee of the Chinese People’s Political Consultative Conference (CPPCC). As mentioned in the reply letter, up to now, a number of medical institutions and clinical research projects have been put on record, which has enabled the stem cell treatment technology to enter clinical research from basic research and strongly promoted the development of stem cell treatment technology in China.
China fully support the application of drug registration for cell therapy products. In recent years, somatic cell therapy for cancer and other refractory diseases has shown a good prospect. In order to meet the clinical needs, further standardize and promote the development of somatic cell therapy, the commission and the State Administration of Food and Drug have conducted discussions on the supervision of cell therapy technology for many times, and organized the application, selection and filing of clinical research institutions of cell therapy technology by referring to the management mode of stem cell clinical research.
Up to 2019, CFDA Drug Review Center has accepted a number of new stem cell drug applications. More and more stem cell companies use the application of stem cell drugs as the only channel to verify the technical strength and product transformation, which is also conducive to the development of the whole industry and promote the implementation of the results.
Some companies in China are actively promoting the application of umbilical cord mesenchymal stem cells to the application of stem cell drugs for specific diseases. Meanwhile, the application of this project has been approved by the FDA IND and entered the clinical phase.
The Future of Stem Cell Therapy in China is Bright
China’s stem cell research has jumped to the forefront of the world, with some directions listing in “leading” positions. It has made a number of significant achievements with international influence in the research fields of cell reprogramming, pluripotency establishment and regulation, and has taken the international lead in the field of characteristic animal resource platform and disease animal model.
At the same time, China has ranked second in the world in terms of the number of published papers and applications of patents in this field for five consecutive years, and has developed a number of self-developed technologies, such as induced pluripotent stem cells obtained by somatic cell reprogramming induced by small molecule compounds, and detailed mapping of early development of human embryos. With the introduction of regulatory policies on stem cell clinical research in China and the accumulation of good theories and technologies in the early stage, the development process of stem cell products will be greatly accelerated and the industry will enter the stage of rapid normative development.
(Part of the article was adapted from the Prospective Economist Application)